Matinas biopharma to present new mat2203 (oral amphotericin b) data during idweek 2022

Interim data from all-oral cohort 4 of the enact trial of mat2203 in cryptococcal meningitis to be revealed along with an overview of the entire phase 2 trial

MTNB Ratings Summary

MTNB Quant Ranking